Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2024
Reporting Period: The filing announces financial results and operational updates for the three months ended June 30, 2024.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) containing the actual financial results. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in text.
- Profit/Loss: Not provided in text.
- Cash Flow: Not provided in text.
- Margins: Not provided in text.
- Debt and Liquidity: Not provided in text.
Material Changes
The filing text does not detail specific material changes in financial performance or operations compared to prior periods. It serves only to notify investors that a press release containing these results has been issued.
Guidance, Outlook, and Other Events
- Operational Update: The Company provided an update on operations for the period ended June 30, 2024, within the attached press release.
- Corporate Presentation: On August 12, 2024, the Company updated its corporate presentation slide deck (Exhibit 99.2).
- Legal Disclaimer: The information in Item 2.02 and the attached exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2024 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and strategic outlook.
- Verify the Company's status as an Emerging Growth Company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol APRE on The Nasdaq Stock Market LLC.